Clinical trials: Objective Response Rate
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Safety and Efficacy of Cellular Drugs, Objective Response Rate of Subjects, Etc
Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors
To investigate the safety and efficacy of CAR-T/CAR-NK cells in patients with recurrent or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, glioma, etc
- Trial name
- NCT06572956
- Testing
- CAR-T/CAR-NK cell injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Hospital of Shandong University